Skip to main navigation Skip to search Skip to main content

Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma

  • Giulio Donati
  • , Micol Ravà
  • , Marco Filipuzzi
  • , Paola Nicoli
  • , Laura Cassina
  • , Alessandro Verrecchia
  • , Mirko Doni
  • , Simona Rodighiero
  • , Federica Parodi
  • , Alessandra Boletta
  • , Christopher P. Vellano
  • , Joseph R. Marszalek
  • , Giulio F. Draetta
  • , Bruno Amati

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple molecular features, such as activation of specific oncogenes (e.g., MYC, BCL2) or a variety of gene expression signatures, have been associated with disease course in diffuse large B-cell lymphoma (DLBCL), although their relationships and implications for targeted therapy remain to be fully unraveled. We report that MYC activity is closely correlated with—and most likely a driver of—gene signatures related to oxidative phosphorylation (OxPhos) in DLBCL, pointing to OxPhos enzymes, in particular mitochondrial electron transport chain (ETC) complexes, as possible therapeutic targets in high-grade MYC-associated lymphomas. In our experiments, indeed, MYC sensitized B cells to the ETC complex I inhibitor IACS-010759. Mechanistically, IACS-010759 triggered the integrated stress response (ISR) pathway, driven by the transcription factors ATF4 and CHOP, which engaged the intrinsic apoptosis pathway and lowered the apoptotic threshold in MYC-overexpressing cells. In line with these findings, the BCL2-inhibitory compound venetoclax synergized with IACS-010759 against double-hit lymphoma (DHL), a high-grade malignancy with concurrent activation of MYC and BCL2. In BCL2-negative lymphoma cells, instead, killing by IACS-010759 was potentiated by the Mcl-1 inhibitor S63845. Thus, combining an OxPhos inhibitor with select BH3-mimetic drugs provides a novel therapeutic principle against aggressive, MYC-associated DLBCL variants.

Original languageEnglish (US)
Pages (from-to)1132-1152
Number of pages21
JournalMolecular oncology
Volume16
Issue number5
DOIs
StatePublished - Mar 2022

Keywords

  • BCL2
  • DLBCL
  • Integrated Stress Response
  • MYC
  • OxPhos
  • chemotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma'. Together they form a unique fingerprint.

Cite this